BridgeBio Pharma, Inc. Logo

BridgeBio Pharma, Inc.

Develops transformative medicines for genetic diseases and genetically driven cancers.

BBIO | US

Overview

Corporate Details

ISIN(s):
US10806X1028
LEI:
Country:
United States of America
Address:
3160 PORTER DR., 94304 PALO ALTO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company's mission is to bridge the gap between advancements in genetic science and patients with unmet needs. It utilizes a development platform that integrates finance and science to accelerate the process of turning scientific discoveries into patient solutions as quickly and safely as possible.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BridgeBio Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan
4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.